Study of AVP 825 for Migraine published in Headache
A study of AVP 825 (sumatriptan powder), from Avanir Pharma for the treatment of acute Migraine has been published in Headache. This randomized study characterized the PK profile of 22 mg sumatriptan delivered through AVP 825 compared with the PK profiles of three sumatriptan products: 20 mg liquid nasal spray, 100 mg oral tablet and 6 mg subcutaneous injection.
It found that AVP-825 was a highly efficient means of sumatriptan delivery, producing a faster rise in sumatriptan plasma concentration, a higher peak exposure, and greater early exposure in the crucial first minutes after treatment than liquid nasal spray, despite delivering a lower dose. See: "Improved Pharmacokinetics of Sumatriptan with Breath Powered Nasal Delivery of Sumatriptan Powder." Mohammad Obaidi et al. Headache: The Journal of Head and Face Pain, Volume 53, Issue 8, pages 1323�1333, September 2013 DOI: 10.1111/head.12167
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.